Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Total Non-Current Liabilities (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Total Non-Current Liabilities data on record, last reported at $37.0 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 11.34% year-over-year to $37.0 million; the TTM value through Sep 2025 reached $37.0 million, down 11.34%, while the annual FY2024 figure was $42.0 million, 9.09% down from the prior year.
  • Total Non-Current Liabilities reached $37.0 million in Q3 2025 per SNTI's latest filing, up from -$32.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $53.3 million in Q4 2022 and bottomed at -$32.2 million in Q2 2025.
  • Average Total Non-Current Liabilities over 5 years is $37.8 million, with a median of $42.1 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: soared 46.73% in 2022, then tumbled 175.34% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $36.3 million in 2021, then soared by 46.73% to $53.3 million in 2022, then decreased by 13.25% to $46.2 million in 2023, then dropped by 9.09% to $42.0 million in 2024, then dropped by 11.99% to $37.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $37.0 million in Q3 2025, -$32.2 million in Q2 2025, and $38.4 million in Q1 2025.